The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.
The acquisition announced Monday will give Crown access to Revance’s Daxxify, a competitor to AbbVie’s Botox, which is indicated for frown lines and for cervical dystonia.
On the heels of the FDA’s denial of its petition, a Delaware district court on Monday handed Novartis another loss in its efforts to keep the market free of Entresto copycats.
By the end of the year, Novo Nordisk intends to make a regulatory filing for the combination of its icodec and semaglutide, keeping its once-weekly insulin program afloat.
The company announced the recent addition of nine leaders that have joined the global agency network EVERSANA INTOUCH to support ongoing growth. The new leaders span the full array of services provided by EVERSANA INTOUCH, from medical communications to strategic planning to creative execution and account planning.
The proceeds from the deal, which is expected to close by early 2025, will help Baxter reduce its debt pile.